Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 6.63
APPY's Cash to Debt is ranked higher than
67% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. APPY: 6.63 )
APPY' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 6.63

Equity to Asset 0.73
APPY's Equity to Asset is ranked higher than
73% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. APPY: 0.73 )
APPY' s 10-Year Equity to Asset Range
Min: -0.05   Max: 0.85
Current: 0.73

-0.05
0.85
F-Score: 3
Z-Score: -0.98
M-Score: 8.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -14454.84
APPY's Operating margin (%) is ranked lower than
57% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. APPY: -14454.84 )
APPY' s 10-Year Operating margin (%) Range
Min: -14454.84   Max: 17.54
Current: -14454.84

-14454.84
17.54
Net-margin (%) -14858.06
APPY's Net-margin (%) is ranked lower than
57% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. APPY: -14858.06 )
APPY' s 10-Year Net-margin (%) Range
Min: -14858.06   Max: 8.99
Current: -14858.06

-14858.06
8.99
ROE (%) -86.17
APPY's ROE (%) is ranked lower than
51% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. APPY: -86.17 )
APPY' s 10-Year ROE (%) Range
Min: -302.97   Max: 8.04
Current: -86.17

-302.97
8.04
ROA (%) -55.44
APPY's ROA (%) is ranked higher than
51% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. APPY: -55.44 )
APPY' s 10-Year ROA (%) Range
Min: -117.03   Max: 5.09
Current: -55.44

-117.03
5.09
ROC (Joel Greenblatt) (%) -360.64
APPY's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. APPY: -360.64 )
APPY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -469.65   Max: 23.23
Current: -360.64

-469.65
23.23
Revenue Growth (%) -66.20
APPY's Revenue Growth (%) is ranked higher than
52% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. APPY: -66.20 )
APPY' s 10-Year Revenue Growth (%) Range
Min: -66.2   Max: -2.3
Current: -66.2

-66.2
-2.3
EBITDA Growth (%) -50.30
APPY's EBITDA Growth (%) is ranked higher than
53% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. APPY: -50.30 )
APPY' s 10-Year EBITDA Growth (%) Range
Min: -50.3   Max: 43.8
Current: -50.3

-50.3
43.8
EPS Growth (%) -49.20
APPY's EPS Growth (%) is ranked higher than
50% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. APPY: -49.20 )
APPY' s 10-Year EPS Growth (%) Range
Min: -49.2   Max: 37.8
Current: -49.2

-49.2
37.8
» APPY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

APPY Guru Trades in

APPY Guru Trades in

Q3 2012

APPY Guru Trades in Q3 2012

Jim Simons 45,785 sh (New)
» More
Q4 2012

APPY Guru Trades in Q4 2012

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with APPY



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.80
APPY's P/B is ranked higher than
68% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. APPY: 2.80 )
APPY' s 10-Year P/B Range
Min: 0.85   Max: 117.07
Current: 2.8

0.85
117.07
P/S 212.77
APPY's P/S is ranked lower than
90% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. APPY: 212.77 )
APPY' s 10-Year P/S Range
Min: 0   Max: 346.37
Current: 212.77

0
346.37
EV-to-EBIT 1000.00
APPY's EV-to-EBIT is ranked lower than
89% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. APPY: 1000.00 )
APPY' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 1000

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.00
APPY's Price/Net Cash is ranked higher than
83% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. APPY: 4.00 )
APPY' s 10-Year Price/Net Cash Range
Min: 1.76   Max: 51.79
Current: 4

1.76
51.79
Price/Net Current Asset Value 4.00
APPY's Price/Net Current Asset Value is ranked higher than
84% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.40 vs. APPY: 4.00 )
APPY' s 10-Year Price/Net Current Asset Value Range
Min: 1.76   Max: 48.57
Current: 4

1.76
48.57
Price/Tangible Book 3.20
APPY's Price/Tangible Book is ranked higher than
74% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. APPY: 3.20 )
APPY' s 10-Year Price/Tangible Book Range
Min: 1.52   Max: 97.5
Current: 3.2

1.52
97.5
Price/Median PS Value 0.80
APPY's Price/Median PS Value is ranked higher than
81% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. APPY: 0.80 )
APPY' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 6.42
Current: 0.8

0.21
6.42
Forward Rate of Return (Yacktman) -324.18
APPY's Forward Rate of Return (Yacktman) is ranked lower than
54% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. APPY: -324.18 )
APPY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -13.5   Max: -5.3
Current: -324.18

-13.5
-5.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AP4B.Germany
Venaxis Inc was organized on July 24, 2000, as a Colorado corporation. In December 2012, the Company's name was changed to Venaxis, Inc., from AspenBio Pharma, Inc. The Company is in the business of development and commercialization of innovative products that address unmet diagnostic and therapeutic needs. The Company's lead product candidate, APPY1, is designed to be a novel blood-based diagnostic test that, if successfully cleared to be marketed by the United States Food and Drug Administration (FDA), will aid, through the test's negative predictive value, in the evaluation of low risk patients initially suspected of having acute appendicitis, thereby helping address the difficult challenge of triaging possible acute appendicitis patients in the hospital emergency department or urgent care settings. The APPY1, is intended to be used by emergency department and urgent care physicians to aid them in the evaluation of possible appendicitis in children, adolescent and young adult patients (ages 2 - 20) that present with abdominal pain. The FDA has regulatory marketing authority in the United States over its APPY1 products. The Company operates under ISO9001-4385 standards for cGMP manufacturing of medical devices. The Company is subject to various environmental laws pertaining to the disposal of hazardous medical waste. It contracts for disposal of hazardous waste with a licensed disposal facility.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide